SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood. 1991; 78: 25202526.
  • 2
    Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood. 1987; 69: 14411449.
  • 3
    Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981; 58: 12031212.
  • 4
    Rees JK. Chemotherapy of acute myeloid leukaemia (AML) in UK: past, present and future. Bone Marrow Transplant. 1989; 4 (Suppl 1): 110–113.
  • 5
    Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991; 77: 16661674.
  • 6
    Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 1992; 10: 11031111.
  • 7
    Wiernik PH, Banks PL, Case DC Jr., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992; 79: 313319.
  • 8
    Wheatley K. Meta-analysis of randomized trials of idarubicin (IDAR) or mitoxantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukemia (AML). AML Cooperative Group. Blood. 1995; 86: 434a.
  • 9
    Bennett JM, Andersen JW, Cassileth PA. Long term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. Leuk Res. 1991; 15: 223227.
  • 10
    Buchner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol. 1985; 3: 15831589.
  • 11
    Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Bodey GP, Freireich EJ. Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia. Cancer. 1986; 58: 16031608.
  • 12
    Peterson BA, Bloomfield CD. Long-term disease-free survival in acute nonlymphocytic leukemia. Blood. 1981; 57: 11441147.
  • 13
    Sauter C, Berchtold W, Fopp M, et al. Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet. 1984; 1: 379382.
  • 14
    Vogler WR, Winton EF, Gordon DS, Raney MR, Go B, Meyer L. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial. Blood. 1984; 63: 10391045.
  • 15
    Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet. 1998; 351: 700708.
  • 16
    Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood. 1992; 79: 19241930.
  • 17
    Harousseau JL, Milpied N, Briere J, et al. Double intensive consolidation chemotherapy in adult acute myeloid leukemia. J Clin Oncol. 1991; 9: 14321437.
  • 18
    Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994; 331: 896903.
  • 19
    Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JL. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol. 1992; 10: 4146.
  • 20
    Tricot G, Boogaerts MA, Vlietinck R, Emonds MP, Verwilghen RL. The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia. Br J Haematol. 1987; 66: 3744.
  • 21
    Wolff SN, Herzig RH, Fay JW, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol. 1989; 7: 12601267.
  • 22
    Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998; 339: 16491656.
  • 23
    Copelan EA, Biggs JC, Thompson JM, et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood. 1991; 78: 838843.
  • 24
    Dinsmore R, Kirkpatrick D, Flomenberg N, et al. Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia. Blood. 1984; 63: 649656.
  • 25
    Cassileth PA, Andersen J, Lazarus HM, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol. 1993; 11: 314319.
  • 26
    Sierra J, Brunet S, Granena A, et al. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation. J Clin Oncol. 1996; 14: 13531363.
  • 27
    Stein AS, O'Donnell MR, Chai A, et al. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol. 1996; 14: 22062216.
  • 28
    Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995; 332: 217223.
  • 29
    Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1997; 90: 29782986.
  • 30
    Tsimberidou AM, Paterakis G, Androutsos G, et al. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leuk Res. 2002; 26: 143154.
  • 31
    Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103: 620625.
  • 32
    Internatinal System for Human Cytogenetic Nomenclature (ICSN). An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, 1995.
  • 33
    National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, MD: National Cancer Institute, 1988.
  • 34
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 35
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163170.
  • 36
    Fleiss JL. Statistical methods for rates and proportions, 2nd edition. New York: John Wiley & Sons, 1981.
  • 37
    Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996; 87: 17101717.
  • 38
    Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997; 89: 23112318.
  • 39
    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 23222333.
  • 40
    Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000; 96: 40754083.
  • 41
    Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999; 107: 6979.
  • 42
    Keating MJ, Smith TL, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia. 1988; 2: 403412.
  • 43
    Webb DK, Harrison G, Stevens RF, et al. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood. 2001; 98: 17141720.
  • 44
    Tallman MS, Rowlings PA, Milone G, et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood. 2000; 96: 12541258.
  • 45
    Cahn JY, Labopin M, Sierra J, et al. No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000; 110: 308314.
  • 46
    Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood. 1997; 90: 16431648.
  • 47
    Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998; 58: 41734179.
  • 48
    Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999; 17: 37673775.
  • 49
    Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood. 2002; 99: 35173523.
  • 50
    Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002; 100: 15321542.
  • 51
    Visani G, Bernasconi P, Boni M, et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia — analysis of 848 patients. Leukemia. 2001; 15: 903909.
  • 52
    Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med. 1996; 334: 14281434.